Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more
Seelos Therapeutics Inc (SEEL) - Total Assets
Latest total assets as of June 2024: $2.38 Million USD
Based on the latest financial reports, Seelos Therapeutics Inc (SEEL) holds total assets worth $2.38 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Seelos Therapeutics Inc - Total Assets Trend (1997–2023)
This chart illustrates how Seelos Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Seelos Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Seelos Therapeutics Inc's total assets of $2.38 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.3% |
| Accounts Receivable | $763.00K | 14.1% |
| Inventory | $1.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1997–2023)
This chart illustrates how Seelos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seelos Therapeutics Inc's current assets represent 99.7% of total assets in 2023, an increase from 8.7% in 1997.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2023, up from 5.7% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
Seelos Therapeutics Inc Competitors by Total Assets
Key competitors of Seelos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Seelos Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Seelos Therapeutics Inc generates 0.41x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Seelos Therapeutics Inc is currently not profitable relative to its asset base.
Seelos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.21 | 2.93 |
| Quick Ratio | 0.08 | 0.11 | 2.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-28.18 Million | $ -44.27 Million | $ 10.67 Million |
Seelos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Seelos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.10 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -76.2% |
| Total Assets | $5.42 Million |
| Market Capitalization | $144.49K USD |
Valuation Analysis
Below Book Valuation: The market values Seelos Therapeutics Inc's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Seelos Therapeutics Inc's assets decreased by 76.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Seelos Therapeutics Inc (1997–2023)
The table below shows the annual total assets of Seelos Therapeutics Inc from 1997 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $5.42 Million | -76.18% |
| 2022-12-31 | $22.75 Million | -72.76% |
| 2021-12-31 | $83.50 Million | +377.31% |
| 2020-12-31 | $17.49 Million | +57.66% |
| 2019-12-31 | $11.10 Million | +195.11% |
| 2018-12-31 | $3.76 Million | -43.93% |
| 2017-12-31 | $6.71 Million | +42.68% |
| 2016-12-31 | $4.70 Million | -40.17% |
| 2015-12-31 | $7.86 Million | -46.96% |
| 2014-12-31 | $14.81 Million | -36.47% |
| 2013-12-31 | $23.31 Million | -2.38% |
| 2012-12-31 | $23.88 Million | +43.71% |
| 2011-12-31 | $16.62 Million | -11.92% |
| 2010-12-31 | $18.86 Million | -9.89% |
| 2009-12-31 | $20.93 Million | +144.62% |
| 2008-12-31 | $8.56 Million | -19.82% |
| 2007-12-31 | $10.67 Million | -46.46% |
| 2006-12-31 | $19.93 Million | +49.52% |
| 2005-12-31 | $13.33 Million | -34.24% |
| 2004-12-31 | $20.27 Million | -12.37% |
| 2003-12-31 | $23.13 Million | +63.60% |
| 2002-12-31 | $14.14 Million | -48.23% |
| 2001-12-31 | $27.31 Million | -31.70% |
| 2000-12-31 | $39.99 Million | +426.18% |
| 1999-12-31 | $7.60 Million | +28.28% |
| 1998-12-31 | $5.92 Million | +153.96% |
| 1997-12-31 | $2.33 Million | -- |